bedaquiline + delamanid + linezolid + moxifloxacin + pyrazinamide

This is a five-drug oral combination regimen specifically investigated for the treatment of rifampicin-resistant tuberculosis (RR-TB). Developed and evaluated in clinical trials by the Shenzhen Third People's Hospital, the regimen consists of bedaquiline, delamanid, linezolid, moxifloxacin, and pyrazinamide. Bedaquiline acts by inhibiting mycobacterial ATP synthase, while delamanid interferes with mycolic acid synthesis. Linezolid provides protein synthesis inhibition via the 50S ribosome, moxifloxacin targets DNA gyrase to prevent bacterial replication, and pyrazinamide is thought to disrupt mycobacterial cell membrane functions. This combination is part of a broader effort to create shortened, all-oral, and highly effective treatments for drug-resistant tuberculosis, reducing the burden of long-term injectable-based therapies.

Other names

BDeLMPy regimenShenzhen regimen